Intraperitoneal radioactive chromic phosphate P 32 in the treatment of ovarian cancer

Journal Article · Tue Dec 01 04:00:00 EST 1987 · South. Med. J.; (United States)

DOI:https://doi.org/10.1097/00007611-198712000-00007· OSTI ID:5468830

Powell, J L; Burrell, M O; Kirchner, A B

The use of intraperitoneal radioisotopes in the management of women with ovarian cancer is controversial. We analyzed the experience with intraperitoneal chromic phosphate P 32 at our institution, from October 1979 to February 1983, in 22 patients with various stages and grades of ovarian malignancy. Survival in stage I is 87.5% and in stage II, 50%. Survival is 88.9% among patients with grade 1 tumors and 33.3% for those with grade 3 lesions. Morbidity related to chromic phosphate P 32 was minimal; small bowel obstruction occurred in only one patient who had also received external pelvic irradiation. Our results suggest that chromic phosphate P 32 is a safe, well tolerated, inexpensive, and effective adjuvant to surgery in the management of selected patients with ovarian malignancy.

• Research Organization: St. Joseph's Hospital, Atlanta, GA
• OSTI ID: 5468830
• Journal Information: South. Med. J.; (United States), Journal Name: South. Med. J.; (United States) Vol. 80:12; ISSN SMJOA
• Country of Publication: United States
• Language: English

Related Subjects

550604* -- Medicine-- Unsealed Radionuclides in Therapy-- (1980-)
62 RADIOLOGY AND NUCLEAR MEDICINE
BETA DECAY RADIOISOTOPES
BETA-MINUS DECAY RADIOISOTOPES
BODY
BODY AREAS
CARCINOMAS
CHROMIUM
DAYS LIVING RADIOISOTOPES
DISEASES
ELEMENTS
FEMALE GENITALS
GONADS
INJECTION
INTAKE
INTRAPERITONEAL INJECTION
ISOTOPES
LIGHT NUCLEI
MEDICINE
METALS
NEOPLASMS
NUCLEAR MEDICINE
NUCLEI
ODD-ODD NUCLEI
ORGANS
OVARIES
OXYGEN COMPOUNDS
PATIENTS
PELVIS
PHOSPHATES
PHOSPHORUS 32
PHOSPHORUS COMPOUNDS
PHOSPHORUS ISOTOPES
RADIOISOTOPES
RADIOLOGY
RADIOTHERAPY
SURVIVAL CURVES
THERAPY
TRANSITION ELEMENTS